1030:
safety and certain health-related quality of life parameters of once-weekly selinexor in combination with once-weekly
Velcade® (bortezomib) plus low-dose dexamethasone (SVd) versus twice-weekly Velcade® plus low-dose dexamethasone (Vd). The primary endpoint of the study was progression-free survival (PFS) and key secondary endpoints included overall response rate (ORR), rate of peripheral neuropathy, and others. Additionally, the BOSTON study allowed for patients on the Vd control arm to crossover to the SVd arm following objective (quantitative) progression of disease verified by an Independent Review Committee (IRC). The BOSTON study was conducted at over 150 clinical sites internationally.
490:
723:
and constitutional symptoms and were consistent with those previously reported from other selinexor studies. Most adverse reactions were manageable with dose modifications and/or standard supportive care. The most common non-hematologic adverse reactions were fatigue (59%), nausea (50%), decreased appetite (35%), and diarrhea (32%) and were mostly Grade 1 and 2 events. The most common Grade 3 and 4 adverse reactions were thrombocytopenia (43%), lymphopenia (38%), fatigue (28%) and anemia (17%).
1034:
increase in median PFS (hazard ratio=0.70; p=0.0075). The SVd group also demonstrated a significantly greater ORR compared to the Vd group (76.4% vs. 62.3%, p=0.0012). Patients who had received only one prior line of therapy also demonstrated a higher ORR on the SVd arm as compared to the Vd arm (80.8% vs. 65.7%, p=0.0082). Importantly, SVd therapy compared to Vd therapy showed consistent PFS benefit and higher ORR across several important subgroups.
727:
thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia. Serious adverse reactions occurred in 46% of people, most often from infection. Thrombocytopenia was the leading cause of dose modifications. Gastrointestinal toxicity developed in 80% of people and any grade hyponatremia developed in 61%. Central neurological adverse reactions occurred in 25% of people, including dizziness and mental status changes.
31:
740:
906:(EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Nexpovio intended for the treatment of relapsed and refractory multiple myeloma. The applicant for this medicinal product is Karyopharm Europe GmbH. Selinexor was approved for medical use in the European Union in March 2021.
3942:
1751:
1577:
1468:
863:. It was approved in the United States in July 2019, on the basis of a single-arm Phase IIb clinical trial. The FDA decided to grant accelerated approval despite a previous recommendation from an FDA Advisory Committee Panel which had voted 8–5 to delay approving the drug until the results from an ongoing Phase III study were known.
722:
In the clinical study (the BOSTON study) used to support FDA approval in patients with multiple myeloma after at least one prior therapy (once-weekly selinexor in combination with once-weekly bortezomib and dexamethasone),the most common adverse reactions were cytopenias, along with gastrointestinal
1029:
In
November 2020, results from the multi-center, Phase III, randomized study (NCT03110562) which evaluated 402 participants with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy were published in The Lancet. The study was designed to compare the efficacy,
977:
The pivotal clinical trial which served to support approval of selinexor for people with relapsed/refractory multiple myeloma was an open-label study of 122 patients known as the STORM trial. In all of the enrolled patients, patients had been treated with a median of seven prior treatment regimens
787:
and its function misregulated in several types of cancer. By inhibiting the XPO1 protein, SINEs lead to a buildup of tumor suppressors in the nucleus of malignant cells and reduce levels of oncogene products which drive cell proliferation. This ultimately leads to cell cycle arrest and death of
1033:
Although the study had one of the highest proportions of patients with high-risk cytogenetics (~50%) as compared with other
Velcade-based studies in previously treated myeloma, the median PFS in the SVd arm was 13.93 months compared to 9.46 months in the Vd arm, representing a 4.47 month (47%)
702:
who have received at least four prior therapies and whose disease is refractory to at least two proteosome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (so-called "quad-refractory" or "penta-refractory" myeloma), for whom no other treatment options are
2088:
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. (November 2020). "Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial".
726:
The most common adverse reactions (incidence ≥20%) in people with diffuse large B-cell lymphoma (DLBCL), excluding laboratory abnormalities, were fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and pyrexia. Grade 3-4 laboratory abnormalities in ≥15% were
660:
for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38
713:
In the
European Union, selinexor is indicated in combination with dexamethasone for the treatment of multiple myeloma in adults who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38
644:
The most common side effects include nausea (feeling sick), vomiting, decreased appetite, weight loss, diarrhea, tiredness, thrombocytopenia (low blood-platelet counts), anaemia (low red-blood cell counts), low levels of white blood cells and hyponatraemia (low blood sodium levels).
1492:
877:(FDA) approved an additional indication for selinexor to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
710:(FDA) approved an additional indication for selinexor to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
880:
Approval was based on SADAL (KCP-330-009; NCT02227251), a multicenter, single-arm, open-label trial in participants with DLBCL after two to five systemic regimens. Participants received selinexor 60 mg orally on days one and three of each week.
1022:
was 26%, including two stringent complete responses; 39% of patients had a minimal response or better. The median duration of response was 4.4 months, median progression-free survival was 3.7 months, and median overall survival was 8.6 months.
693:
Selinexor is approved in combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy. Selinexor is also approved for use in combination with the steroid
884:
In
December 2020, the FDA expanded selinexor's approved indication to include its combination with bortezomib and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.
1045:. In this phase 2 randomized placebo-controlled single-blind trial named XPORT-CoV-1001 with a total of 190 participants with severe COVID-19, treatment with selinexor resulted in higher mortality (16% vs. 9%) and more
1602:
1488:
1736:
566:
665:
and dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy. In clinical trials, it was associated with a high incidence of severe side effects, including
730:
The prescribing information provides warnings and precautions for thrombocytopenia, neutropenia, gastrointestinal toxicity, hyponatremia, serious infection, neurological toxicity, and embryo-fetal toxicity.
209:
1775:
1453:
1685:
1412:
164:
1594:
2144:
1194:
2220:
1728:
1026:
As of 2019, phase I/II and III trials are ongoing, including the use of selinexor in other cancers and in combinations with other drugs used for multiple myeloma.
899:
799:
Inhibiting XPO1 affects many different cells in the body which may explain the incidence of adverse reactions to selinexor. Thrombocytopenia, for example, is a
61:
2920:
580:
1867:
1800:
2063:
1933:
1768:
1015:
2152:
1946:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1251:
Text was copied from this source which is copyright
European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
3896:
2213:
1489:"Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After at Least One Prior Therapy"
1441:
752:
606:
3503:
1677:
1404:
1238:
1121:
3992:
2655:
2611:
2489:
1095:
2414:
1562:
2206:
2141:
1184:
3136:
2930:
319:
194:
93:
3549:
2551:
2441:
859:
Selinexor was developed by
Karyopharm Therapeutics, a pharmaceutical company focused on the development of drugs that target
3962:
3471:
3454:
3329:
3093:
2471:
2170:
for "Evaluation of
Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus)" at
3932:
1528:
3203:
2799:
1861:
1556:
1447:
874:
707:
678:
653:
409:
1897:
3913:
3405:
2198:
828:
469:
112:
2585:
927:
649:
3771:
3651:
3641:
1927:
1855:
1232:
903:
682:
291:
3823:
3756:
3726:
3344:
2594:
1816:"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia"
1629:"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond"
3901:
3808:
3626:
3341:
2827:
2675:
2602:
808:
287:
150:
3706:
3696:
3429:
3271:
2055:
1922:
1261:
971:
610:
260:
3972:
2978:
2795:
2765:
2625:
1046:
1019:
848:
840:
618:
3376:
3253:
2774:
2690:
951:
939:
485:
298:
803:
and dose-dependent effect, occurring because selinexor causes a buildup of the transcription factor
3982:
3967:
3661:
3561:
3540:
3261:
3083:
2915:
2646:
2542:
1003:
832:
800:
747:
of nuclear transport. Selinexor inhibits this process at the nuclear export receptor (upper right).
638:
344:
157:
3987:
3977:
2719:
2171:
2124:
123:
3868:
1814:
Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister CC, Gabrail N, et al. (February 2018).
2749:
2729:
2714:
458:
3843:
3417:
2251:
2116:
2037:
1996:
1837:
1794:
1658:
1627:
Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. (February 2018).
1376:
1326:
967:
919:
860:
764:
233:
221:
43:
1227:
866:
Selinexor in combination with dexamethasone was granted accelerated approval and was granted
661:
monoclonal antibody. In
December 2020, selinexor was approved by the FDA in combination with
353:
3848:
3605:
3320:
2954:
2939:
2660:
2106:
2098:
2027:
1986:
1976:
1827:
1648:
1640:
1366:
1316:
1308:
983:
768:
699:
667:
506:
252:
418:
3946:
3287:
3249:
3040:
2462:
2377:
2148:
2014:
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. (August 2019).
963:
784:
489:
279:
270:
2187:
1550:
714:
monoclonal antibody, and who have demonstrated disease progression on the last therapy.
3907:
3441:
3032:
2526:
2390:
2277:
2247:
2234:
1991:
1964:
1653:
1628:
1321:
1296:
1038:
959:
824:
2102:
3956:
3781:
3741:
3111:
2984:
2865:
2808:
2566:
2515:
2128:
1755:
1581:
1472:
1355:"Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma"
1353:
Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, Cornell RF (May 2018).
923:
844:
812:
744:
695:
657:
378:
85:
1965:"Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents"
1312:
3828:
3792:
3676:
3666:
3620:
3616:
3578:
3486:
3276:
3215:
3211:
3192:
3187:
3166:
3155:
2969:
2963:
2949:
2944:
2875:
2870:
2823:
2709:
2576:
2556:
2485:
2434:
2424:
2238:
2230:
999:
995:
979:
947:
943:
915:
776:
671:
622:
177:
172:
2166:
1832:
1815:
1069:
71:
3873:
3853:
3838:
3833:
3818:
3776:
3746:
3686:
3656:
3600:
3573:
3446:
3387:
3359:
3349:
3302:
3266:
3182:
3144:
3126:
3121:
3101:
3078:
3049:
3027:
3007:
2997:
2848:
2833:
2813:
2699:
2630:
2616:
2571:
2504:
2499:
2476:
2451:
2419:
2362:
2325:
2302:
2287:
2282:
2267:
1007:
991:
870:
designation. The FDA granted the approval of Xpovio to Karyopharm Therapeutics.
867:
760:
79:
1371:
1354:
3863:
3766:
3761:
3736:
3731:
3721:
3716:
3711:
3681:
3671:
3636:
3631:
3611:
3566:
3554:
3529:
3524:
3514:
3496:
3491:
3481:
3476:
3434:
3422:
3410:
3382:
3369:
3364:
3334:
3297:
3292:
3230:
3225:
3171:
3116:
3068:
3054:
3002:
2989:
2958:
2891:
2880:
2853:
2843:
2838:
2784:
2739:
2734:
2635:
2599:
2531:
2521:
2510:
2494:
2446:
2429:
2405:
2357:
2345:
2297:
1981:
1518:
1011:
987:
685:. Selinexor was approved for medical use in the European Union in March 2021.
662:
630:
542:
3878:
3858:
3813:
3797:
3701:
3646:
3595:
3519:
3509:
3464:
3451:
3392:
3354:
3282:
3220:
3161:
3150:
3106:
3063:
3022:
3016:
3012:
2974:
2901:
2896:
2886:
2858:
2818:
2779:
2754:
2744:
2704:
2350:
2340:
2335:
2330:
2292:
1889:
789:
780:
634:
626:
65:
2120:
2041:
2016:"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma"
2000:
1841:
1662:
1380:
1330:
2032:
2015:
1147:
22:
3787:
3751:
3691:
3459:
3397:
3177:
3073:
3045:
2724:
2561:
1644:
1523:
1189:
1042:
955:
935:
931:
836:
815:(platelet-producing cells) and thus slowing production of new platelets.
772:
389:
107:
1729:"FDA approves selinexor for relapsed/refractory diffuse large B-cell ly"
914:
Under the codename KPT-330, selinexor was tested in several preclinical
739:
398:
2680:
2581:
2395:
2256:
2142:
LVHN Among Early Participants to Test Cancer Drug as COVID-19 Treatment
2111:
364:
30:
2320:
946:, and a wide range of advanced or refractory solid tumors, including
283:
1678:"New Treatment for Refractory Multiple Myeloma Granted FDA Approval"
938:. In humans, early clinical trials (phase I) have been conducted in
703:
available. It is the first drug to be approved for this indication.
656:(FDA) in July 2019, for use in combination with the corticosteroid
588:
C1=CN=C(C=N1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
438:
1405:"FDA approves new multiple myeloma drug despite toxicity concerns"
804:
738:
565:
556:
449:
275:
1754:
This article incorporates text from this source, which is in the
1580:
This article incorporates text from this source, which is in the
1471:
This article incorporates text from this source, which is in the
1917:
1915:
1297:"Atomic basis of CRM1-cargo recognition, release and inhibition"
756:
614:
429:
239:
2202:
227:
102:
796:, this effect appeared to spare normal (non-malignant) cells.
1442:"FDA approves new treatment for refractory multiple myeloma"
1096:"Updates to the Prescribing Medicines in Pregnancy database"
775:, and proteins involved in governing cell growth, from the
621:
of several proteins involved in cancer-cell growth from the
474:
1483:
1481:
203:
134:
1519:"FDA Approves Selinexor for Refractory Multiple Myeloma"
216:
2083:
2081:
3930:
3588:
3539:
3319:
3312:
3248:
3202:
3135:
3092:
2929:
2914:
2794:
2764:
2689:
2674:
2645:
2541:
2461:
2404:
2387:
2376:
2312:
2265:
2246:
554:
541:
505:
500:
468:
448:
428:
408:
388:
363:
343:
310:
297:
269:
259:
251:
193:
188:
163:
149:
122:
92:
78:
60:
52:
42:
37:
1963:Parikh K, Cang S, Sekhri A, Liu D (October 2014).
1179:
1177:
1175:
1173:
1171:
1723:
1721:
1719:
1717:
1715:
1713:
1711:
1709:
1707:
1705:
1703:
1018:but had disease that continued to progress. The
377:
1958:
1956:
1954:
1952:
1622:
1620:
1222:
1220:
1218:
1216:
1214:
1212:
811:, preventing their differentiation into mature
352:
1348:
1346:
1344:
1342:
1340:
1290:
1288:
1286:
1284:
1282:
1064:
1062:
900:Committee for Medicinal Products for Human Use
2214:
8:
843:groove of exportin 1. Although this bond is
111:
21:
1512:
1510:
3316:
2926:
2686:
2401:
2384:
2262:
2221:
2207:
2199:
488:
29:
2110:
2031:
1990:
1980:
1890:"Xpovio (selinexor) FDA Approval History"
1831:
1652:
1436:
1434:
1432:
1430:
1370:
1359:Clinical Lymphoma, Myeloma & Leukemia
1320:
759:(also known as XPO1 or CRM1). XPO1 is a
417:
3937:
1398:
1396:
1394:
1392:
1390:
1185:"Xpovio- selinexor tablet, film coated"
1058:
1016:hematopoietic stem cell transplantation
755:(SINEs), selinexor works by binding to
585:
484:
397:
324:
84:
2056:"KPT-330 OR Selinexor Clinical Trials"
1799:: CS1 maint: archived copy as title (
1792:
1605:from the original on 16 September 2020
1415:from the original on 25 September 2020
1100:Therapeutic Goods Administration (TGA)
1074:Therapeutic Goods Administration (TGA)
753:selective inhibitors of nuclear export
698:in people with relapsed or refractory
20:
1565:from the original on 20 November 2019
1456:from the original on 20 November 2019
613:. It works by blocking the action of
607:selective inhibitor of nuclear export
457:
70:
7:
2194:. U.S. National Library of Medicine.
1969:Journal of Hematology & Oncology
1936:from the original on 1 February 2021
1531:from the original on 15 January 2021
1266:Union Register of medicinal products
1122:"Summary Basis of Decision - Xpovio"
176:
2490:ribonucleotide reductase inhibitors
2066:from the original on 29 August 2021
2020:The New England Journal of Medicine
1739:from the original on 12 August 2020
1688:from the original on 12 August 2020
1197:from the original on 29 August 2021
437:
368:
2656:Ribonucleotide reductase inhibitor
2612:Ribonucleotide reductase inhibitor
2153:Lehigh Valley Hospital–Cedar Crest
827:compound, developed by means of a
14:
2415:Dihydrofolate reductase inhibitor
1870:from the original on 9 April 2021
1781:from the original on 28 July 2021
1733:U.S. Food and Drug Administration
1599:U.S. Food and Drug Administration
1595:"New Drug Therapy Approvals 2019"
1495:from the original on 8 March 2021
1295:Fung HY, Chook YM (August 2014).
1014:); nearly all had also undergone
637:. It is the first drug with this
335:′-pyrazin-2-ylprop-2-enehydrazide
3940:
1900:from the original on 9 July 2019
1749:
1575:
1466:
1241:from the original on 2 June 2021
529:
523:
517:
1923:"Nexpovio: Pending EC decision"
1856:"Drug Approval Package: Xpovio"
1551:"Drug Trials Snapshots: Xpovio"
1313:10.1016/j.semcancer.2014.03.002
1037:In 2020, selinexor underwent a
823:Selinexor is a fully synthetic
767:of several proteins, including
629:, which ultimately arrests the
2552:Thymidylate synthase inhibitor
2442:Thymidylate synthase inhibitor
1452:(Press release). 3 July 2019.
1262:"Nexpovio Product information"
743:Schematic illustration of the
535:
511:
1:
2472:Adenosine deaminase inhibitor
2313:Block microtubule disassembly
2103:10.1016/S0140-6736(20)32292-3
1862:Food and Drug Administration
1833:10.1182/blood-2017-08-797886
1557:Food and Drug Administration
1448:Food and Drug Administration
1403:Feuerstein A (3 July 2019).
1049:(23% vs. 16%) than placebo.
875:Food and Drug Administration
708:Food and Drug Administration
679:Food and Drug Administration
654:Food and Drug Administration
331:)-3-{3--1,2,4-triazol-1-yl}-
829:structure-based drug design
681:(FDA) considers it to be a
4009:
2155:(LVHN) website, 7 May 2020
1372:10.1016/j.clml.2018.03.003
1301:Seminars in Cancer Biology
928:non-small-cell lung cancer
601:sold under the brand name
501:Chemical and physical data
3993:Trifluoromethyl compounds
3891:
3772:Omacetaxine mepesuccinate
3652:Ciltacabtagene autoleucel
3642:Brexucabtagene autoleucel
1982:10.1186/s13045-014-0078-0
1928:European Medicines Agency
1676:Barrett J (3 July 2019).
1517:Mulcahy N (3 July 2019).
1233:European Medicines Agency
904:European Medicines Agency
683:first-in-class medication
576:
315:
28:
3824:Talimogene laherparepvec
3757:Nadofaragene firadenovec
3727:Lisocabtagene maraleucel
2676:Topoisomerase inhibitors
2595:DNA polymerase inhibitor
974:has also been reported.
934:, and acute and chronic
898:On 28 January 2021, the
809:hematopoietic stem cells
3627:Axicabtagene ciloleucel
2231:chemotherapeutic agents
2192:Drug Information Portal
2147:24 January 2021 at the
978:including conventional
873:In June 2020, the U.S.
706:In June 2020, the U.S.
672:low blood sodium levels
3809:Sitimagene ceradenovec
3707:Idecabtagene vicleucel
3272:Methyl aminolevulinate
2164:Clinical trial number
1047:serious adverse events
972:acute myeloid leukemia
748:
648:Selinexor was granted
617:and thus blocking the
611:anti-cancer medication
282:, and conjugation, by
3283:Porphyrin derivatives
2979:Melphalan flufenamide
2626:Hypomethylating agent
2235:antineoplastic agents
2033:10.1056/NEJMoa1903455
1020:overall response rate
918:of cancer, including
841:nuclear export signal
742:
142:Use should be avoided
3963:Antineoplastic drugs
3612:Asparagine depleters
3541:Receptor antagonists
3455:+abiraterone acetate
2097:(10262): 1563–1573.
1645:10.1038/leu.2017.329
1601:. 31 December 2019.
952:head and neck cancer
940:non-Hodgkin lymphoma
650:accelerated approval
3662:Denileukin diftitox
3562:Retinoid X receptor
3262:Aminolevulinic acid
3084:Triethylenemelamine
2916:Crosslinking of DNA
2647:Deoxyribonucleotide
2586:+gimeracil/oteracil
1932:. 29 January 2021.
1237:. 25 January 2021.
1148:"Product monograph"
1004:monoclonal antibody
889:Society and culture
833:induced-fit docking
735:Mechanism of action
668:low platelet counts
639:mechanism of action
605:among others, is a
212:(Prescription only)
25:
3918:Never to phase III
2720:Etirinotecan pegol
2172:ClinicalTrials.gov
2060:ClinicalTrials.gov
1193:. 19 August 2019.
1102:. 21 December 2022
807:in the nucleus of
749:
3928:
3927:
3887:
3886:
3844:Tigilanol tiglate
3321:Enzyme inhibitors
3244:
3243:
3240:
3239:
2940:Nitrogen mustards
2910:
2909:
2670:
2669:
2372:
2371:
1128:. 23 October 2014
1041:for treatment of
970:in patients with
968:Compassionate use
920:pancreatic cancer
861:nuclear transport
831:process known as
769:tumor suppressors
765:nuclear transport
596:
595:
567:Interactive image
470:CompTox Dashboard
243:
231:
219:
207:
138:
105:
4000:
3945:
3944:
3943:
3936:
3849:Tisagenlecleucel
3606:Arsenic trioxide
3317:
3250:Photosensitizers
3041:Alkyl sulfonates
2955:Cyclophosphamide
2927:
2866:Anthracenediones
2687:
2661:Hydroxycarbamide
2402:
2385:
2263:
2223:
2216:
2209:
2200:
2195:
2174:
2162:
2156:
2139:
2133:
2132:
2114:
2085:
2076:
2075:
2073:
2071:
2052:
2046:
2045:
2035:
2011:
2005:
2004:
1994:
1984:
1960:
1947:
1945:
1943:
1941:
1919:
1910:
1909:
1907:
1905:
1886:
1880:
1879:
1877:
1875:
1866:. 26 July 2019.
1852:
1846:
1845:
1835:
1811:
1805:
1804:
1798:
1790:
1788:
1786:
1780:
1773:
1765:
1759:
1753:
1752:
1748:
1746:
1744:
1735:. 22 June 2020.
1725:
1698:
1697:
1695:
1693:
1673:
1667:
1666:
1656:
1624:
1615:
1614:
1612:
1610:
1591:
1585:
1579:
1578:
1574:
1572:
1570:
1561:. 16 July 2019.
1547:
1541:
1540:
1538:
1536:
1514:
1505:
1504:
1502:
1500:
1485:
1476:
1470:
1469:
1465:
1463:
1461:
1438:
1425:
1424:
1422:
1420:
1400:
1385:
1384:
1374:
1350:
1335:
1334:
1324:
1292:
1277:
1276:
1274:
1272:
1258:
1252:
1250:
1248:
1246:
1224:
1207:
1206:
1204:
1202:
1181:
1166:
1165:
1163:
1161:
1152:
1144:
1138:
1137:
1135:
1133:
1118:
1112:
1111:
1109:
1107:
1092:
1086:
1085:
1083:
1081:
1066:
984:targeted therapy
835:. It binds to a
788:cancer cells by
700:multiple myeloma
569:
549:
537:
531:
525:
519:
513:
493:
492:
478:
476:
461:
441:
421:
401:
381:
371:
370:
356:
302:
241:
238:
229:
226:
218:
215:
205:
202:
180:
136:
133:
115:
104:
101:
88:
74:
48:Xpovio, Nexpovio
33:
26:
24:
16:Anti-cancer drug
4008:
4007:
4003:
4002:
4001:
3999:
3998:
3997:
3953:
3952:
3951:
3941:
3939:
3931:
3929:
3924:
3923:
3908:Clinical trials
3883:
3589:Other/ungrouped
3584:
3535:
3308:
3288:Porfimer sodium
3236:
3198:
3131:
3088:
2918:
2906:
2790:
2760:
2678:
2666:
2641:
2537:
2457:
2393:
2391:antimetabolites
2389:
2388:DNA precursors/
2380:
2378:DNA replication
2368:
2308:
2278:Vinca alkaloids
2254:
2242:
2227:
2186:
2183:
2178:
2177:
2163:
2159:
2149:Wayback Machine
2140:
2136:
2087:
2086:
2079:
2069:
2067:
2054:
2053:
2049:
2013:
2012:
2008:
1962:
1961:
1950:
1939:
1937:
1921:
1920:
1913:
1903:
1901:
1896:. 3 July 2019.
1888:
1887:
1883:
1873:
1871:
1854:
1853:
1849:
1813:
1812:
1808:
1791:
1784:
1782:
1778:
1771:
1769:"Archived copy"
1767:
1766:
1762:
1750:
1742:
1740:
1727:
1726:
1701:
1691:
1689:
1675:
1674:
1670:
1626:
1625:
1618:
1608:
1606:
1593:
1592:
1588:
1576:
1568:
1566:
1549:
1548:
1544:
1534:
1532:
1516:
1515:
1508:
1498:
1496:
1487:
1486:
1479:
1467:
1459:
1457:
1440:
1439:
1428:
1418:
1416:
1402:
1401:
1388:
1352:
1351:
1338:
1294:
1293:
1280:
1270:
1268:
1260:
1259:
1255:
1244:
1242:
1228:"Nexpovio EPAR"
1226:
1225:
1210:
1200:
1198:
1183:
1182:
1169:
1159:
1157:
1150:
1146:
1145:
1141:
1131:
1129:
1120:
1119:
1115:
1105:
1103:
1094:
1093:
1089:
1079:
1077:
1076:. 24 March 2022
1068:
1067:
1060:
1055:
964:prostate cancer
912:
896:
891:
857:
847:, it is slowly
839:residue in the
821:
763:which performs
737:
720:
718:Adverse effects
691:
592:
589:
584:
583:
572:
547:
534:
528:
522:
516:
496:
486:DTXSID801026013
472:
464:
444:
424:
404:
384:
367:
359:
339:
336:
323:
322:
300:
280:glucuronidation
261:Protein binding
253:Pharmacokinetic
247:
184:
152:
145:
125:
118:
17:
12:
11:
5:
4006:
4004:
3996:
3995:
3990:
3985:
3980:
3975:
3970:
3965:
3955:
3954:
3950:
3949:
3926:
3925:
3922:
3921:
3920:
3919:
3916:
3905:
3899:
3893:
3892:
3889:
3888:
3885:
3884:
3882:
3881:
3876:
3871:
3866:
3861:
3856:
3851:
3846:
3841:
3836:
3831:
3826:
3821:
3816:
3811:
3806:
3801:
3795:
3784:
3779:
3774:
3769:
3764:
3759:
3754:
3749:
3744:
3739:
3734:
3729:
3724:
3719:
3714:
3709:
3704:
3699:
3694:
3689:
3684:
3679:
3674:
3669:
3664:
3659:
3654:
3649:
3644:
3639:
3634:
3629:
3624:
3608:
3603:
3598:
3592:
3590:
3586:
3585:
3583:
3582:
3570:
3558:
3545:
3543:
3537:
3536:
3534:
3533:
3527:
3522:
3517:
3512:
3500:
3494:
3489:
3484:
3479:
3468:
3462:
3457:
3449:
3442:PARP inhibitor
3438:
3426:
3414:
3402:
3401:
3400:
3395:
3390:
3385:
3373:
3367:
3362:
3357:
3352:
3338:
3325:
3323:
3314:
3310:
3309:
3307:
3306:
3300:
3295:
3290:
3279:
3274:
3269:
3264:
3258:
3256:
3246:
3245:
3242:
3241:
3238:
3237:
3235:
3234:
3228:
3223:
3218:
3208:
3206:
3200:
3199:
3197:
3196:
3190:
3185:
3174:
3169:
3164:
3159:
3147:
3141:
3139:
3133:
3132:
3130:
3129:
3124:
3119:
3114:
3109:
3104:
3098:
3096:
3094:Platinum-based
3090:
3089:
3087:
3086:
3081:
3076:
3071:
3059:
3058:
3052:
3036:
3035:
3030:
3025:
3020:
3010:
3005:
2993:
2992:
2987:
2982:
2972:
2967:
2961:
2952:
2947:
2935:
2933:
2924:
2912:
2911:
2908:
2907:
2905:
2904:
2899:
2894:
2889:
2884:
2878:
2873:
2862:
2856:
2851:
2846:
2841:
2836:
2831:
2821:
2816:
2809:Anthracyclines
2804:
2802:
2792:
2791:
2789:
2788:
2782:
2770:
2768:
2762:
2761:
2759:
2758:
2752:
2747:
2742:
2737:
2732:
2727:
2722:
2717:
2712:
2707:
2695:
2693:
2684:
2672:
2671:
2668:
2667:
2665:
2664:
2651:
2649:
2643:
2642:
2640:
2639:
2633:
2621:
2620:
2607:
2606:
2590:
2589:
2579:
2574:
2569:
2564:
2559:
2547:
2545:
2539:
2538:
2536:
2535:
2529:
2527:Mercaptopurine
2518:
2513:
2508:
2502:
2497:
2481:
2480:
2467:
2465:
2459:
2458:
2456:
2455:
2449:
2438:
2432:
2427:
2422:
2410:
2408:
2399:
2382:
2374:
2373:
2370:
2369:
2367:
2366:
2354:
2348:
2343:
2338:
2333:
2328:
2316:
2314:
2310:
2309:
2307:
2306:
2300:
2295:
2290:
2285:
2273:
2271:
2260:
2244:
2243:
2229:Intracellular
2228:
2226:
2225:
2218:
2211:
2203:
2197:
2196:
2182:
2181:External links
2179:
2176:
2175:
2157:
2134:
2077:
2047:
2026:(8): 727–738.
2006:
1948:
1911:
1881:
1847:
1826:(8): 855–863.
1806:
1760:
1699:
1682:Pharmacy Times
1668:
1639:(2): 252–262.
1616:
1586:
1542:
1506:
1477:
1426:
1386:
1365:(5): 335–345.
1336:
1278:
1253:
1208:
1167:
1139:
1113:
1087:
1070:"Xpovio APMDS"
1057:
1056:
1054:
1051:
1039:clinical trial
960:ovarian cancer
911:
908:
902:(CHMP) of the
895:
892:
890:
887:
856:
853:
825:small-molecule
820:
817:
813:megakaryocytes
783:; it is often
736:
733:
719:
716:
690:
687:
594:
593:
591:
590:
587:
579:
578:
577:
574:
573:
571:
570:
562:
560:
552:
551:
545:
539:
538:
532:
526:
520:
514:
509:
503:
502:
498:
497:
495:
494:
481:
479:
466:
465:
463:
462:
454:
452:
446:
445:
443:
442:
434:
432:
426:
425:
423:
422:
414:
412:
406:
405:
403:
402:
394:
392:
386:
385:
383:
382:
374:
372:
361:
360:
358:
357:
349:
347:
341:
340:
338:
337:
326:
318:
317:
316:
313:
312:
308:
307:
304:
295:
294:
273:
267:
266:
263:
257:
256:
249:
248:
246:
245:
236:
224:
213:
199:
197:
191:
190:
186:
185:
183:
182:
169:
167:
161:
160:
155:
153:administration
147:
146:
144:
143:
140:
130:
128:
120:
119:
117:
116:
98:
96:
90:
89:
82:
76:
75:
68:
58:
57:
54:
50:
49:
46:
40:
39:
35:
34:
15:
13:
10:
9:
6:
4:
3:
2:
4005:
3994:
3991:
3989:
3986:
3984:
3981:
3979:
3976:
3974:
3971:
3969:
3966:
3964:
3961:
3960:
3958:
3948:
3938:
3934:
3917:
3915:
3912:
3911:
3909:
3906:
3903:
3900:
3898:
3895:
3894:
3890:
3880:
3877:
3875:
3872:
3870:
3867:
3865:
3862:
3860:
3857:
3855:
3852:
3850:
3847:
3845:
3842:
3840:
3837:
3835:
3832:
3830:
3827:
3825:
3822:
3820:
3817:
3815:
3812:
3810:
3807:
3805:
3802:
3799:
3796:
3794:
3790:
3789:
3785:
3783:
3782:Tabelecleucel
3780:
3778:
3775:
3773:
3770:
3768:
3765:
3763:
3760:
3758:
3755:
3753:
3750:
3748:
3745:
3743:
3742:Lurbinectedin
3740:
3738:
3735:
3733:
3730:
3728:
3725:
3723:
3720:
3718:
3715:
3713:
3710:
3708:
3705:
3703:
3700:
3698:
3695:
3693:
3690:
3688:
3685:
3683:
3680:
3678:
3675:
3673:
3670:
3668:
3665:
3663:
3660:
3658:
3655:
3653:
3650:
3648:
3645:
3643:
3640:
3638:
3635:
3633:
3630:
3628:
3625:
3622:
3618:
3614:
3613:
3609:
3607:
3604:
3602:
3599:
3597:
3594:
3593:
3591:
3587:
3580:
3576:
3575:
3571:
3568:
3564:
3563:
3559:
3556:
3552:
3551:
3547:
3546:
3544:
3542:
3538:
3531:
3528:
3526:
3523:
3521:
3518:
3516:
3513:
3511:
3507:
3505:
3501:
3498:
3495:
3493:
3490:
3488:
3485:
3483:
3480:
3478:
3474:
3473:
3469:
3466:
3463:
3461:
3458:
3456:
3453:
3450:
3448:
3444:
3443:
3439:
3436:
3432:
3431:
3427:
3424:
3420:
3419:
3415:
3412:
3408:
3407:
3403:
3399:
3396:
3394:
3391:
3389:
3386:
3384:
3381:
3380:
3379:
3378:
3374:
3371:
3368:
3366:
3363:
3361:
3358:
3356:
3353:
3351:
3347:
3346:
3343:
3339:
3336:
3332:
3331:
3327:
3326:
3324:
3322:
3318:
3315:
3311:
3304:
3301:
3299:
3296:
3294:
3291:
3289:
3285:
3284:
3280:
3278:
3275:
3273:
3270:
3268:
3265:
3263:
3260:
3259:
3257:
3255:
3251:
3247:
3232:
3229:
3227:
3224:
3222:
3219:
3217:
3213:
3210:
3209:
3207:
3205:
3204:Intercalation
3201:
3194:
3191:
3189:
3186:
3184:
3180:
3179:
3175:
3173:
3170:
3168:
3165:
3163:
3160:
3157:
3153:
3152:
3148:
3146:
3143:
3142:
3140:
3138:
3134:
3128:
3125:
3123:
3120:
3118:
3115:
3113:
3112:Dicycloplatin
3110:
3108:
3105:
3103:
3100:
3099:
3097:
3095:
3091:
3085:
3082:
3080:
3077:
3075:
3072:
3070:
3067:
3065:
3061:
3060:
3056:
3053:
3051:
3047:
3044:
3042:
3038:
3037:
3034:
3031:
3029:
3026:
3024:
3021:
3018:
3014:
3011:
3009:
3006:
3004:
3001:
2999:
2995:
2994:
2991:
2988:
2986:
2985:Prednimustine
2983:
2980:
2976:
2973:
2971:
2968:
2965:
2962:
2960:
2956:
2953:
2951:
2948:
2946:
2943:
2941:
2937:
2936:
2934:
2932:
2928:
2925:
2922:
2917:
2913:
2903:
2900:
2898:
2895:
2893:
2890:
2888:
2885:
2882:
2879:
2877:
2874:
2872:
2868:
2867:
2863:
2860:
2857:
2855:
2852:
2850:
2847:
2845:
2842:
2840:
2837:
2835:
2832:
2829:
2825:
2822:
2820:
2817:
2815:
2811:
2810:
2806:
2805:
2803:
2801:
2800:Intercalation
2797:
2793:
2786:
2783:
2781:
2777:
2776:
2772:
2771:
2769:
2767:
2763:
2756:
2753:
2751:
2748:
2746:
2743:
2741:
2738:
2736:
2733:
2731:
2728:
2726:
2723:
2721:
2718:
2716:
2713:
2711:
2708:
2706:
2702:
2701:
2697:
2696:
2694:
2692:
2688:
2685:
2682:
2677:
2673:
2662:
2658:
2657:
2653:
2652:
2650:
2648:
2644:
2637:
2634:
2632:
2628:
2627:
2623:
2622:
2618:
2614:
2613:
2609:
2608:
2604:
2603:+daunorubicin
2601:
2597:
2596:
2592:
2591:
2587:
2583:
2580:
2578:
2575:
2573:
2570:
2568:
2567:Doxifluridine
2565:
2563:
2560:
2558:
2554:
2553:
2549:
2548:
2546:
2544:
2540:
2533:
2530:
2528:
2524:
2523:
2519:
2517:
2516:Rabacfosadine
2514:
2512:
2509:
2506:
2503:
2501:
2498:
2496:
2492:
2491:
2487:
2483:
2482:
2478:
2474:
2473:
2469:
2468:
2466:
2464:
2460:
2453:
2450:
2448:
2444:
2443:
2439:
2436:
2433:
2431:
2428:
2426:
2423:
2421:
2417:
2416:
2412:
2411:
2409:
2407:
2403:
2400:
2397:
2392:
2386:
2383:
2379:
2375:
2364:
2360:
2359:
2355:
2352:
2349:
2347:
2344:
2342:
2339:
2337:
2334:
2332:
2329:
2327:
2323:
2322:
2318:
2317:
2315:
2311:
2304:
2301:
2299:
2296:
2294:
2291:
2289:
2286:
2284:
2280:
2279:
2275:
2274:
2272:
2269:
2264:
2261:
2258:
2253:
2249:
2245:
2240:
2236:
2232:
2224:
2219:
2217:
2212:
2210:
2205:
2204:
2201:
2193:
2189:
2185:
2184:
2180:
2173:
2169:
2168:
2161:
2158:
2154:
2150:
2146:
2143:
2138:
2135:
2130:
2126:
2122:
2118:
2113:
2108:
2104:
2100:
2096:
2092:
2084:
2082:
2078:
2065:
2061:
2057:
2051:
2048:
2043:
2039:
2034:
2029:
2025:
2021:
2017:
2010:
2007:
2002:
1998:
1993:
1988:
1983:
1978:
1974:
1970:
1966:
1959:
1957:
1955:
1953:
1949:
1935:
1931:
1929:
1924:
1918:
1916:
1912:
1899:
1895:
1891:
1885:
1882:
1869:
1865:
1863:
1857:
1851:
1848:
1843:
1839:
1834:
1829:
1825:
1821:
1817:
1810:
1807:
1802:
1796:
1777:
1770:
1764:
1761:
1757:
1756:public domain
1738:
1734:
1730:
1724:
1722:
1720:
1718:
1716:
1714:
1712:
1710:
1708:
1706:
1704:
1700:
1687:
1683:
1679:
1672:
1669:
1664:
1660:
1655:
1650:
1646:
1642:
1638:
1634:
1630:
1623:
1621:
1617:
1604:
1600:
1596:
1590:
1587:
1583:
1582:public domain
1564:
1560:
1558:
1552:
1546:
1543:
1530:
1526:
1525:
1520:
1513:
1511:
1507:
1494:
1490:
1484:
1482:
1478:
1474:
1473:public domain
1455:
1451:
1449:
1443:
1437:
1435:
1433:
1431:
1427:
1414:
1410:
1406:
1399:
1397:
1395:
1393:
1391:
1387:
1382:
1378:
1373:
1368:
1364:
1360:
1356:
1349:
1347:
1345:
1343:
1341:
1337:
1332:
1328:
1323:
1318:
1314:
1310:
1306:
1302:
1298:
1291:
1289:
1287:
1285:
1283:
1279:
1267:
1263:
1257:
1254:
1240:
1236:
1234:
1229:
1223:
1221:
1219:
1217:
1215:
1213:
1209:
1196:
1192:
1191:
1186:
1180:
1178:
1176:
1174:
1172:
1168:
1156:
1149:
1143:
1140:
1127:
1126:Health Canada
1123:
1117:
1114:
1101:
1097:
1091:
1088:
1075:
1071:
1065:
1063:
1059:
1052:
1050:
1048:
1044:
1040:
1035:
1031:
1027:
1024:
1021:
1017:
1013:
1009:
1005:
1001:
997:
993:
989:
985:
981:
975:
973:
969:
965:
961:
957:
953:
949:
945:
941:
937:
933:
929:
925:
924:breast cancer
921:
917:
916:animal models
909:
907:
905:
901:
893:
888:
886:
882:
878:
876:
871:
869:
864:
862:
854:
852:
850:
846:
842:
838:
834:
830:
826:
818:
816:
814:
810:
806:
802:
797:
795:
791:
786:
785:overexpressed
782:
778:
774:
770:
766:
762:
758:
754:
746:
741:
734:
732:
728:
724:
717:
715:
711:
709:
704:
701:
697:
696:dexamethasone
688:
686:
684:
680:
675:
673:
669:
664:
659:
658:dexamethasone
655:
651:
646:
642:
640:
636:
633:and leads to
632:
628:
624:
620:
616:
612:
608:
604:
600:
586:
582:
575:
568:
564:
563:
561:
558:
553:
546:
544:
540:
510:
508:
504:
499:
491:
487:
483:
482:
480:
471:
467:
460:
456:
455:
453:
451:
447:
440:
436:
435:
433:
431:
427:
420:
416:
415:
413:
411:
407:
400:
396:
395:
393:
391:
387:
380:
376:
375:
373:
366:
362:
355:
351:
350:
348:
346:
342:
334:
330:
325:
321:
314:
309:
305:
303:
296:
293:
289:
285:
281:
277:
274:
272:
268:
264:
262:
258:
254:
250:
244: Rx-only
237:
235:
225:
223:
214:
211:
201:
200:
198:
196:
192:
187:
179:
174:
171:
170:
168:
166:
162:
159:
156:
154:
148:
141:
132:
131:
129:
127:
121:
114:
109:
100:
99:
97:
95:
91:
87:
83:
81:
77:
73:
69:
67:
63:
59:
55:
51:
47:
45:
41:
38:Clinical data
36:
32:
27:
19:
3973:Orphan drugs
3829:Tazemetostat
3803:
3793:Alitretinoin
3786:
3697:Estramustine
3677:Elsamitrucin
3667:Eflornithine
3621:Pegaspargase
3617:Asparaginase
3610:
3579:Testolactone
3572:
3560:
3548:
3502:
3487:Panobinostat
3470:
3440:
3428:
3416:
3404:
3375:
3340:
3328:
3281:
3277:Padeliporfin
3216:Dactinomycin
3212:Streptomyces
3193:Temozolomide
3188:Mitozolomide
3176:
3167:Mitobronitol
3156:Procarbazine
3149:
3137:Nonclassical
3062:
3039:
3033:Streptozocin
2998:Nitrosoureas
2996:
2970:Chlorambucil
2964:Trofosfamide
2950:Chlormethine
2945:Bendamustine
2938:
2876:Mitoxantrone
2871:Losoxantrone
2864:
2824:Daunorubicin
2807:
2773:
2710:Camptothecin
2698:
2654:
2624:
2610:
2593:
2577:Fluorouracil
2557:Capecitabine
2550:
2520:
2484:
2470:
2440:
2435:Pralatrexate
2425:Methotrexate
2413:
2356:
2319:
2276:
2191:
2165:
2160:
2137:
2094:
2090:
2068:. Retrieved
2059:
2050:
2023:
2019:
2009:
1972:
1968:
1938:. Retrieved
1926:
1902:. Retrieved
1893:
1884:
1872:. Retrieved
1859:
1850:
1823:
1819:
1809:
1785:30 September
1783:. Retrieved
1763:
1741:. Retrieved
1732:
1690:. Retrieved
1681:
1671:
1636:
1632:
1609:15 September
1607:. Retrieved
1598:
1589:
1567:. Retrieved
1554:
1545:
1533:. Retrieved
1522:
1497:. Retrieved
1458:. Retrieved
1445:
1417:. Retrieved
1408:
1362:
1358:
1304:
1300:
1269:. Retrieved
1265:
1256:
1243:. Retrieved
1231:
1199:. Retrieved
1188:
1158:. Retrieved
1154:
1142:
1130:. Retrieved
1125:
1116:
1104:. Retrieved
1099:
1090:
1078:. Retrieved
1073:
1036:
1032:
1028:
1025:
1000:pomalidomide
996:lenalidomide
980:chemotherapy
976:
948:colon cancer
944:blast crisis
913:
897:
894:Legal status
883:
879:
872:
865:
858:
822:
798:
793:
777:cell nucleus
750:
729:
725:
721:
712:
705:
692:
689:Medical uses
676:
652:by the U.S.
647:
643:
623:cell nucleus
602:
598:
597:
459:CHEBI:229764
354:1393477-72-9
332:
328:
299:Elimination
195:Legal status
189:Legal status
94:License data
18:
3904:from market
3874:Vorasidenib
3854:Trabectedin
3839:Tiazofurine
3834:Tebentafusp
3819:Tagraxofusp
3777:Plitidepsin
3747:Mitoguazone
3687:Epacadostat
3657:Demecolcine
3601:Aflibercept
3574:Sex steroid
3447:Fuzuloparib
3388:Carfilzomib
3360:Palbociclib
3350:Abemaciclib
3303:Verteporfin
3267:Efaproxiral
3183:Dacarbazine
3145:Altretamine
3127:Satraplatin
3122:Oxaliplatin
3102:Carboplatin
3079:Triaziquone
3050:Mannosulfan
3028:Ranimustine
3008:Fotemustine
2849:Pirarubicin
2834:Doxorubicin
2828:+cytarabine
2814:Aclarubicin
2775:Podophyllum
2700:Camptotheca
2631:Azacitidine
2617:Gemcitabine
2572:Floxuridine
2505:Fludarabine
2500:Clofarabine
2486:Halogenated
2477:Pentostatin
2452:Raltitrexed
2420:Aminopterin
2363:Ixabepilone
2358:Epothilones
2326:Cabazitaxel
2303:Vinorelbine
2288:Vincristine
2283:Vinblastine
2268:microtubule
2188:"Selinexor"
2167:NCT04349098
2112:2436/623569
2070:20 November
1904:20 November
1569:20 November
1499:21 December
1460:20 November
1201:20 November
1132:28 November
1008:daratumumab
992:carfilzomib
868:orphan drug
801:mechanistic
761:karyopherin
751:Like other
609:used as an
550: g·mol
311:Identifiers
278:oxidation,
80:MedlinePlus
53:Other names
44:Trade names
3983:Teratogens
3968:Hydrazides
3957:Categories
3869:Verdinexor
3864:Venetoclax
3767:Oblimersen
3762:Navitoclax
3737:Lucanthone
3732:Lonidamine
3722:Lifileucel
3717:Ivosidenib
3712:Imetelstat
3682:Enasidenib
3672:Elesclomol
3637:Bexarotene
3632:Belzutifan
3567:Bexarotene
3555:Atrasentan
3530:Umbralisib
3525:Idelalisib
3515:Copanlisib
3497:Vorinostat
3492:Romidepsin
3482:Entinostat
3477:Belinostat
3435:Masoprocol
3423:Tiazofurin
3411:Anagrelide
3383:Bortezomib
3370:Seliciclib
3365:Ribociclib
3345:inhibitors
3335:Tipifarnib
3298:Temoporfin
3293:Talaporfin
3231:Plicamycin
3226:Mitomycins
3172:Pipobroman
3151:Hydrazines
3117:Nedaplatin
3069:Carboquone
3064:Aziridines
3055:Treosulfan
3003:Carmustine
2990:Uramustine
2959:Ifosfamide
2931:Alkylating
2892:Bisantrene
2881:Pixantrone
2854:Valrubicin
2844:Idarubicin
2839:Epirubicin
2785:Teniposide
2740:Lurtotecan
2735:Irinotecan
2636:Decitabine
2600:Cytarabine
2543:Pyrimidine
2532:Tioguanine
2522:Thiopurine
2511:Nelarabine
2495:Cladribine
2447:Pemetrexed
2430:Pemetrexed
2406:Folic acid
2346:Paclitaxel
2298:Vinflunine
1940:1 February
1053:References
1012:isatuximab
988:bortezomib
849:reversible
757:exportin 1
663:bortezomib
631:cell cycle
615:exportin 1
555:3D model (
543:Molar mass
419:31TZ62FO8F
345:CAS Number
320:IUPAC name
271:Metabolism
3988:Triazoles
3978:Pyrazines
3914:Phase III
3902:Withdrawn
3879:Vosaroxin
3859:Veliparib
3814:Sotorasib
3804:Selinexor
3798:Tretinoin
3788:Retinoids
3702:Glasdegib
3647:Celecoxib
3596:Adagrasib
3520:Duvelisib
3510:Alpelisib
3465:Rucaparib
3452:Niraparib
3393:Oprozomib
3355:Alvocidib
3221:Bleomycin
3178:Triazenes
3162:Etoglucid
3107:Cisplatin
3023:Nimustine
3017:Semustine
3013:Lomustine
2975:Melphalan
2902:Menogaril
2897:Crisnatol
2887:Amsacrine
2859:Zorubicin
2819:Amrubicin
2780:Etoposide
2755:Topotecan
2750:Silatecan
2745:Rubitecan
2730:Gimatecan
2715:Cositecan
2705:Belotecan
2381:inhibitor
2351:Tesetaxel
2341:Ortataxel
2336:Larotaxel
2331:Docetaxel
2293:Vindesine
2129:226308726
1894:Drugs.com
1307:: 52–61.
1106:2 January
936:leukemias
932:lymphomas
819:Chemistry
790:apoptosis
781:cytoplasm
773:oncogenes
745:Ran cycle
677:The U.S.
635:apoptosis
627:cytoplasm
619:transport
599:Selinexor
306:6–8 hours
301:half-life
151:Routes of
124:Pregnancy
113:Selinexor
72:Monograph
66:Drugs.com
23:Selinexor
3947:Medicine
3752:Mitotane
3692:Eribulin
3460:Olaparib
3398:Ixazomib
3074:Thiotepa
3046:Busulfan
2725:Exatecan
2562:Carmofur
2270:assembly
2233: /
2145:Archived
2121:33189178
2064:Archived
2042:31433920
2001:25316614
1934:Archived
1898:Archived
1868:Archived
1842:29203585
1795:cite web
1776:Archived
1737:Archived
1686:Archived
1663:29257139
1633:Leukemia
1603:Archived
1563:Archived
1529:Archived
1524:Medscape
1493:Archived
1454:Archived
1413:Archived
1381:29610030
1331:24631835
1239:Archived
1195:Archived
1190:DailyMed
1160:24 March
1043:COVID-19
1002:, and a
956:melanoma
910:Research
845:covalent
837:cysteine
794:In vitro
390:DrugBank
379:71481097
165:ATC code
158:By mouth
126:category
108:DailyMed
2681:S phase
2582:Tegafur
2396:S phase
2321:Taxanes
2257:M phase
1992:4200201
1874:24 June
1743:24 June
1654:5808071
1322:4108548
1271:3 March
1155:hres.ca
1080:4 April
855:History
779:to the
625:to the
548:443.313
507:Formula
399:DB11942
365:PubChem
220::
181:)
175: (
173:L01XX66
139: D
110::
86:a619044
56:KPT-330
3933:Portal
3897:WHO-EM
3506:(Pi3K)
2463:Purine
2266:Block
2127:
2119:
2091:Lancet
2040:
1999:
1989:
1975:: 78.
1840:
1692:7 July
1661:
1651:
1535:6 July
1419:6 July
1379:
1329:
1319:
1245:27 May
962:, and
603:Xpovio
581:SMILES
439:D11222
284:CYP3A4
234:℞-only
232:
222:℞-only
208:
106:
3418:IMPDI
3313:Other
2125:S2CID
1930:(EMA)
1864:(FDA)
1860:U.S.
1820:Blood
1779:(PDF)
1772:(PDF)
1559:(FDA)
1555:U.S.
1450:(FDA)
1446:U.S.
1235:(EMA)
1151:(PDF)
986:with
805:STAT3
557:JSmol
450:ChEBI
276:Liver
3504:PIKI
3472:HDAC
2921:CCNS
2117:PMID
2072:2019
2038:PMID
1997:PMID
1942:2021
1906:2019
1876:2020
1838:PMID
1801:link
1787:2022
1745:2020
1694:2019
1659:PMID
1611:2020
1571:2019
1537:2019
1501:2020
1462:2019
1421:2019
1409:STAT
1377:PMID
1327:PMID
1273:2023
1247:2021
1203:2019
1162:2024
1134:2022
1108:2023
1082:2022
670:and
430:KEGG
410:UNII
290:and
255:data
62:AHFS
3550:ERA
3406:PhI
3377:PrI
3342:CDK
3254:PDT
2252:MIs
2248:SPs
2239:L01
2107:hdl
2099:doi
2095:396
2028:doi
2024:381
1987:PMC
1977:doi
1828:doi
1824:131
1649:PMC
1641:doi
1367:doi
1317:PMC
1309:doi
1010:or
475:EPA
369:CID
292:GST
288:UGT
265:95%
178:WHO
3959::
3910::
3430:LI
3330:FI
2796:II
2766:II
2588:))
2190:.
2151:,
2123:.
2115:.
2105:.
2093:.
2080:^
2062:.
2058:.
2036:.
2022:.
2018:.
1995:.
1985:.
1971:.
1967:.
1951:^
1925:.
1914:^
1892:.
1858:.
1836:.
1822:.
1818:.
1797:}}
1793:{{
1774:.
1731:.
1702:^
1684:.
1680:.
1657:.
1647:.
1637:32
1635:.
1631:.
1619:^
1597:.
1553:.
1527:.
1521:.
1509:^
1491:.
1480:^
1444:.
1429:^
1411:.
1407:.
1389:^
1375:.
1363:18
1361:.
1357:.
1339:^
1325:.
1315:.
1305:27
1303:.
1299:.
1281:^
1264:.
1230:.
1211:^
1187:.
1170:^
1153:.
1124:.
1098:.
1072:.
1061:^
998:,
994:,
990:,
982:,
966:.
958:,
954:,
950:,
942:,
930:,
926:,
922:,
851:.
792:.
771:,
674:.
641:.
521:11
515:17
327:(2
286:,
240:EU
228:US
217:CA
210:S4
204:AU
135:AU
103:US
3935::
3800:)
3791:(
3623:)
3619:/
3615:(
3581:)
3577:(
3569:)
3565:(
3557:)
3553:(
3532:)
3508:(
3499:)
3475:(
3467:)
3445:(
3437:)
3433:(
3425:)
3421:(
3413:)
3409:(
3372:)
3348:(
3337:)
3333:(
3305:)
3286:(
3252:/
3233:)
3214:(
3195:)
3181:(
3158:)
3154:(
3066::
3057:)
3048:(
3043::
3019:)
3015:(
3000::
2981:)
2977:(
2966:)
2957:(
2942::
2923:)
2919:(
2883:)
2869:(
2861:)
2830:)
2826:(
2812:(
2798:+
2787:)
2778:(
2757:)
2703:(
2691:I
2683:)
2679:(
2663:)
2659:(
2638:)
2629:(
2619:)
2615:(
2605:)
2598:(
2584:(
2555:(
2534:)
2525:(
2507:)
2493:(
2488:/
2479:)
2475:(
2454:)
2445:(
2437:)
2418:(
2398:)
2394:(
2365:)
2361:(
2353:)
2324:(
2305:)
2281:(
2259:)
2255:(
2250:/
2241:)
2237:(
2222:e
2215:t
2208:v
2131:.
2109::
2101::
2074:.
2044:.
2030::
2003:.
1979::
1973:7
1944:.
1908:.
1878:.
1844:.
1830::
1803:)
1789:.
1758:.
1747:.
1696:.
1665:.
1643::
1613:.
1584:.
1573:.
1539:.
1503:.
1475:.
1464:.
1423:.
1383:.
1369::
1333:.
1311::
1275:.
1249:.
1205:.
1164:.
1136:.
1110:.
1084:.
1006:(
559:)
536:O
533:7
530:N
527:6
524:F
518:H
512:C
477:)
473:(
333:N
329:Z
242::
230::
206::
137::
64:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
